Is Cullinan Therapeutics, Inc. (CGEM) a Buy, Sell, or Hold?
NASDAQ : CGEM
Cullinan Therapeutics, Inc. — Institutional Ownership
$19.46 USD
$1.18 (6.46%)
- Volume
- 346.72K
- Average Volume
- 933.5K
- Market Capitalization
- $1.2B
- P/E Ratio
- -5.77
- Dividend Yield
- 0.00%
- Price Target
- $33.50
- Year High
- $19.55
- Year Low
- $5.68
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $8.42
Institutional Ownership Summary
Institutional Ownership %
18.27%
Investors Holding
57
change: -120.0 | last: 177
Increased Positions
34
change: -66.0 | last: 100
Reduced Positions
16
change: -26.0 | last: 42
New Positions
15
change: -25.0 | last: 40
Sold Positions
131
change: 111.0 | last: 20
Total Calls
-
Total Puts
-
Put-Call Ratio
0.00
change: -28.9448 | last: 0.2894
Total Invested
196.82M
Beneficial Ownership Filings
| Filing Date | Reporting Person | Amount Beneficially Owned | % of Class |
|---|---|---|---|
| 2026-05-15 | BIOTECHNOLOGY VALUE FUND L P | 3.55M | 5.80% |
| 2026-03-26 | The Vanguard Group | - | 0.00% |
| 2026-03-04 | Kynam Capital Management, LP | 3.11M | 5.27% |
| 2026-02-17 | BIOTECHNOLOGY VALUE FUND L P | 3.3M | 5.60% |
| 2026-01-30 | The Vanguard Group | 3.3M | 5.58% |
| 2025-11-14 | Citadel Advisors LLC | 1.84M | 3.10% |
| 2025-11-14 | LYNX1 CAPITAL MANAGEMENT LP | 5.77M | 9.80% |
| 2025-11-13 | Deerfield Mgmt, L.P. | 2.93M | 4.95% |
| 2025-10-30 | The Vanguard Group | 2.94M | 4.98% |
| 2025-10-10 | Lynx1 Capital Management LP | 8.55M | 14.50% |
| 2025-08-14 | Lynx1 Capital Management LP | 4.4M | 7.50% |
| 2025-08-06 | Citadel Advisors LLC | 2.51M | 4.30% |
| 2024-11-08 | (1) BlackRock, Inc. | 4.34M | 7.50% |
| 2024-10-22 | (1) BlackRock, Inc. | 4.34M | 7.50% |
| 2024-04-24 | James E. Flynn | 3.28M | 5.71% |
| 2024-04-24 | Deerfield Partners, L.P. | 3.28M | 5.71% |
| 2024-04-24 | Deerfield Mgmt, L.P. | 3.28M | 5.71% |
| 2024-04-24 | Deerfield Management Company, L.P. | 3.28M | 5.71% |
| 2024-02-14 | Blue Owl Capital Holdings LP | 3.42M | 7.99% |
| 2024-01-29 | (1) BlackRock, Inc. | 2.46M | 5.80% |
| 2023-02-03 | (1) BlackRock, Inc. | 2.51M | 5.50% |
| 2022-02-14 | Biotechnology Value Fund II, L.P. | 2.19M | 5.00% |
| 2022-02-14 | BVF I GP LLC | 2.79M | 6.40% |
| 2022-02-14 | BVF II GP LLC | 2.19M | 5.00% |
| 2022-02-14 | Biotechnology Value Trading Fund OS LP | 301.67K | 1.00% |
| 2022-02-14 | BVF Partners OS Ltd. | 301.67K | 1.00% |
| 2022-02-14 | BVF GP HOLDINGS LLC | 4.98M | 11.40% |
| 2022-02-14 | BVF Partners L.P. | 5.37M | 12.30% |
| 2022-02-14 | BVF Inc. | 5.37M | 12.30% |
| 2022-02-14 | Mark N. Lampert | 5.37M | 12.30% |
| 2022-02-14 | Biotechnology Value Fund, L.P. | 2.79M | 6.40% |
| 2022-02-11 | CHI Advisors LLC | 2.48M | 5.67% |
| 2022-02-10 | Morana Jovan-Embiricos | 6.28M | 14.30% |
| 2022-02-10 | F2 Vision Management Sarl | 2.91M | 6.70% |
| 2022-02-10 | F2 Vision SCS | 2.91M | 6.70% |
| 2022-02-10 | F2 Bioscience I 2017 Ltd. | 639.3K | 1.50% |
| 2022-02-10 | F2 MC, LLC | 214.8K | 0.50% |
| 2022-02-10 | F2 GC, LLC | 104.76K | 0.20% |
| 2022-02-10 | Globeways Holdings Ltd. | 2.1M | 4.80% |
| 2022-02-10 | F2 MG Ltd. | 325.33K | 0.70% |
| 2022-02-10 | Globeways Holdings II Ltd. | 1.01M | 2.30% |
| 2022-02-10 | F2-TPO Investments, LLC | 622.18K | 1.40% |
| 2022-02-10 | F2 Bio TD, LLC | 71599.0 | 0.20% |
| 2022-02-09 | The Vanguard Group - 23-1945930 | 2.37M | 5.42% |
| 2021-12-20 | BVF II GP LLC | 1.81M | 4.10% |
| 2021-12-20 | Biotechnology Value Trading Fund OS LP | 255.8K | 1.00% |
| 2021-12-20 | BVF Partners OS Ltd. | 255.8K | 1.00% |
| 2021-12-20 | BVF GP HOLDINGS LLC | 4.06M | 9.30% |
| 2021-12-20 | BVF Inc. | 4.39M | 10.10% |
| 2021-12-20 | BVF Partners L.P. | 4.39M | 10.10% |
| 2021-12-20 | Mark N. Lampert | 4.39M | 10.10% |
| 2021-12-20 | Biotechnology Value Fund, L.P. | 2.26M | 5.20% |
| 2021-12-20 | Biotechnology Value Fund II, L.P. | 1.81M | 4.10% |
| 2021-12-20 | BVF I GP LLC | 2.26M | 5.20% |
| 2021-11-08 | BVF Partners L.P. | 2.61M | 6.00% |
| 2021-11-08 | BVF II GP LLC | 1.02M | 2.30% |
| 2021-11-08 | Biotechnology Value Trading Fund OS LP | 157.98K | 1.00% |
| 2021-11-08 | BVF Partners OS Ltd. | 157.98K | 1.00% |
| 2021-11-08 | BVF GP HOLDINGS LLC | 2.41M | 5.50% |
| 2021-11-08 | Mark N. Lampert | 2.61M | 6.00% |
| 2021-11-08 | Biotechnology Value Fund, L.P. | 1.39M | 3.20% |
| 2021-11-08 | BVF I GP LLC | 1.39M | 3.20% |
| 2021-11-08 | Biotechnology Value Fund II, L.P. | 1.02M | 2.30% |
| 2021-11-08 | BVF Inc. | 2.61M | 6.00% |
| 2021-01-19 | Gadicke | 8.55M | 19.60% |
| 2021-01-19 | Impact Management GP LLC | 7.91M | 18.30% |
| 2021-01-19 | Impact Fund, L.P. | 7.91M | 18.30% |
| 2021-01-19 | Impact Fund (Cayman) LP | 7.91M | 18.30% |
| 2021-01-19 | Impact Management LP | 7.91M | 18.30% |
| 2021-01-15 | James Tananbaum (“Tananbaum”) | 3.64M | 8.80% |
| 2021-01-15 | Foresite Capital Fund V, L.P. (“FCF V”) | 2.73M | 6.60% |
| 2021-01-15 | Foresite Capital Management V, LLC (“FCM V”) | 2.73M | 6.60% |
| 2021-01-15 | Foresite Capital Opportunity Fund V, L.P. (“FCF Opp V”) | 910.47K | 2.20% |
| 2021-01-15 | Foresite Capital Opportunity Management V, LLC (“FCM Opp V”) | 910.47K | 2.20% |
CGEM Enterprise Value History
Annual
| Date | Stock Price | Shares Outstanding | Market Cap | Cash & Equivalents | Total Debt | Enterprise Value |
|---|---|---|---|---|---|---|
| 2025-12-31 | $10.35 | 59.05M | $611.17M | $88.33M | $2.68M | $525.52M |
| 2024-12-31 | $12.18 | 53.77M | $654.93M | $83M | $2.15M | $574.08M |
| 2023-12-31 | $10.19 | 41.51M | $422.96M | $98.43M | $3.59M | $328.11M |
| 2022-12-31 | $10.55 | 45.16M | $476.48M | $156.15M | $5.19M | $325.52M |
| 2021-12-31 | $15.43 | 44.29M | $683.43M | $59.77M | -$ | $623.65M |
| 2020-12-31 | $29.91 | 43.52M | $1.3B | $168.2M | -$ | $1.13B |
| 2019-12-31 | $29.91 | 1.02M | $30.42M | $63.25M | -$ | -$32.83M |
| 2018-12-31 | $29.91 | 800K | $23.93M | $33.83M | -$ | -$9.9M |
Quarterly
| Date | Stock Price | Shares Outstanding | Market Cap | Cash & Equivalents | Total Debt | Enterprise Value |
|---|---|---|---|---|---|---|
| 2026-06-30 | $18.21 | 61.49M | $1.12B | $78.64M | $2.07M | $1.04B |
| 2026-03-31 | $14.21 | 59.2M | $841.25M | $75.08M | $2.38M | $768.55M |
| 2025-12-31 | $10.35 | 59.2M | $612.73M | $88.33M | $2.68M | $527.08M |
| 2025-09-30 | $5.93 | 59.02M | $349.96M | $103.34M | $1.19M | $247.81M |
| 2025-06-30 | $7.53 | 59.02M | $444.38M | $72.82M | $1.52M | $373.08M |
| 2025-03-31 | $7.57 | 58.9M | $445.91M | $76.66M | $1.84M | $371.1M |
| 2024-12-31 | $12.18 | 58.58M | $713.5M | $83M | $2.15M | $632.65M |
| 2024-09-30 | $16.74 | 58.34M | $976.56M | $102.08M | $2.45M | $876.92M |
| 2024-06-30 | $16.73 | 55.05M | $921.02M | $115.02M | $2.73M | $808.73M |
| 2024-03-31 | $17.65 | 43.01M | $759.14M | $74.23M | $3.17M | $688.09M |
| 2023-12-31 | $10.19 | 42.79M | $436.07M | $98.43M | $3.59M | $341.23M |
| 2023-09-30 | $9.05 | 42.73M | $386.74M | $64.85M | $5.92M | $327.81M |